• Home
  • Search Results
  • Lectin-decorated nanoparticles enhance binding to the inflamed tissue in experimental colitis.

Lectin-decorated nanoparticles enhance binding to the inflamed tissue in experimental colitis.

Journal of controlled release : official journal of the Controlled Release Society (2014-06-10)
Brice Moulari, Arnaud Béduneau, Yann Pellequer, Alf Lamprecht
ABSTRACT

A major limitation in the drug treatment of inflammatory bowel disease is the inability to deliver the drug selectively towards the inflamed tissues. Nanotechnology-based drug delivery systems have led to an amelioration of the therapeutic selectivity but still the majority of the entrapped drug is eliminated without exercising a therapeutic effect. Here, lectin-decorated drug loaded nanoparticles (NP) are suggested for active targeting and selective adhesion to the inflamed tissue in experimental colitis. Peanut (PNA) and wheat germ (WGA) lectins were covalently bound to the surface of NP and were tested for their stability and degree of bioadhesion in cell culture. In-vivo, the selectivity of bioadhesion and distribution of NP throughout the intestinal tract as well as the therapeutic benefit for glucocorticoid loaded lectin-NP was studied in murine colitis models. Quantitative adhesion analyses showed that lectin-conjugated NP exhibited a much higher binding and selectivity to inflamed tissue compared to plain NP (PNA conjugates: 52.2±5.6%; WGA conjugates: 22.0±0.8%; plain NP: 18.6±9.8%). Lectin-associated NP revealed a further increase in the selectivity of bioadhesion towards inflamed tissues which partially translates into increased therapeutic efficiency. In terms of therapeutic efficiency, all glucocorticoid containing formulations revealed an enhanced therapeutic effect with lectin conjugates especially PNA-NP (myeloperoxidase: 55±37U/g; TNF-alpha: 3880±380U/g) compared to plain NP (myeloperoxidase: 145±98U/g; TNF-alpha: 6971±1157U/g). Targeted NP by using lectins, especially with PNA, as stable targeting moiety in the gastrointestinal tract appears to be a very promising tool in future treatment of inflammatory bowel disease.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
2-Mercaptoethanol, ≥99.0%
Sigma-Aldrich
Ethyl acetate, ACS reagent, ≥99.5%
Sigma-Aldrich
2-Mercaptoethanol, for molecular biology, suitable for electrophoresis, suitable for cell culture, BioReagent, 99% (GC/titration)
Sigma-Aldrich
Ethyl acetate, anhydrous, 99.8%
Sigma-Aldrich
Ethyl acetate, suitable for HPLC, ≥99.7%
Sigma-Aldrich
Ethyl acetate, puriss. p.a., ACS reagent, reag. ISO, reag. Ph. Eur., ≥99.5% (GC)
Sigma-Aldrich
Ethyl acetate, HPLC Plus, for HPLC, GC, and residue analysis, 99.9%
Sigma-Aldrich
2-Mercaptoethanol, BioUltra, for molecular biology, ≥99.0% (GC)
Sigma-Aldrich
Ethyl acetate, puriss., meets analytical specification of Ph. Eur., BP, NF, ≥99.5% (GC)
Sigma-Aldrich
Ethyl acetate, suitable for HPLC, ≥99.8%
Sigma-Aldrich
3,6-Dimethyl-1,4-dioxane-2,5-dione, 99%
Supelco
Ethyl acetate, analytical standard
Sigma-Aldrich
Glycolide, ≥99%
Supelco
Ethyl Acetate, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
2-Mercaptoethanol, for HPLC derivatization, LiChropur, ≥99.0% (GC)
Sigma-Aldrich
Ethyl acetate, ≥99%, FCC, FG
Sigma-Aldrich
Ethyl acetate, natural, ≥99%, FCC, FG
Supelco
Betamethasone, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Ethyl acetate, ReagentPlus®, ≥99.8%
Sigma-Aldrich
Betamethasone, ≥98%
Sigma-Aldrich
Ethyl acetate, ACS reagent, ≥99.5%
Sigma-Aldrich
Ethyl acetate, ACS reagent, ≥99.5%
USP
Betamethasone, United States Pharmacopeia (USP) Reference Standard
Betamethasone, European Pharmacopoeia (EP) Reference Standard
Supelco
Betamethasone, VETRANAL®, analytical standard
Sigma-Aldrich
Ethyl acetate, biotech. grade, ≥99.8%
Supelco
Ethyl acetate, HPLC grade, 99.8%
Sigma-Aldrich
Betamethasone, meets USP testing specifications
Sigma-Aldrich
Ethyl acetate
Sigma-Aldrich
Ethyl acetate